rapıd3 score can predıct dısease actıvıty ın prımary sjögren’s syndrome

INTRODUCTION: Sjögren’s syndrome (SS) is a chronic autoimmune disease that causes salivary and lacrimal gland dysfunction, resulting in oral and ocular dryness. The European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) is a systemic disease activity index measuring disease activity in patients with SS. The ESSDAI includes 12 domains. EULAR SS patient-reported index (ESSPRI) is used to evaluate dryness, fatigue, and pain symptoms, and their impact on the disease. Routine Assessment of Patient Index Data 3 (RAPID3) is used to evaluate disease activity in patients with rheumatoid arthritis which is another inflammatory disorder. This study aims to evaluate whether RAPID3 is useful in primary SS.
METHODS: In this cross-sectional study, 30 patients with primary SS were enrolled. ESSDAI, ESSPRI and RAPID3 scores were recorded. Chi-square, Mann Whitney U test and Pearson correlation analysis were performed for the statistical analysis.
RESULTS: Mean ESSDAI, ESSPRI and RAPID3 scores were 3.8±3.6, 5.8±1.7, and 14.8±5.2, respectively. ESSPRI and RAPID3 scores were positively correlated (r=0.669, p<0.001). In addition, when we set the cut-off value to 12 on the RAPID3 score (>12 accepted as active, and ≤12 accepted as inactive), ESSPRI score was significantly higher in active patients (6.4±1.4 vs. 4.1±1.4, p=0.002). However, there was no relationship between RAPID3 and ESSDAI scores.
DISCUSSION AND CONCLUSION: In SS, it is difficult to detect disease activity. Comorbid psychosomatic diseases affect the set detecting global disease activity. These results suggest that RAPID3 may be useful to detect disease activity in primary SS.